NeuroScientific Biopharmaceuticals Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net loss was AUD 1.23 million compared to AUD 3.06 million a year ago. Basic loss per share from continuing operations was AUD 0.0085 compared to AUD 0.0213 a year ago.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.048 AUD | -7.69% | -9.43% | +9.09% |
1st Jan change | Capi. | |
---|---|---|
+9.09% | 4.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023